You can share it to WeChat via the Qr code.
Enter the applet sharing event using WeChat scan.
In 2015, BIOMAP founded the first Chemical drug R&D Forum. After eight sessions , it has been working with Chinese small molecule pharmaceutical enterprises all the way, witnessing the historical process from generic drugs to innovative drugs, and accompanying the development and growth of small molecule pharmaceutical industry across the region. The forum gathers KOL in Drug Discovery, Regulatory Affairs, pharmaceutical CMC and other fields to discuss and promote the development of Small Molecule Chemical Drugs across the region!
As more and more innovative pharmaceutical enterprises reach the end of the marathon and get product launched, and more and more new technologies innovate the traditional pharmaceutical pattern, pharmaceutical companies are still facing severe challenges:
· How to face the continuous questions from pre NDA meeting ？
· Facing the severe challenge of homogenization, how to differentiate the layout of the next product?
· Under the system of medical insurance and centralized procurement of drugs, how to establish the competition barriers of new drugs that really meet the clinical needs?
· How do AI/PROTACand other revolutionary technologies improve the druggability and accelerate clinical transformation?
In the spring of 2022, PharmaCon 2022 The 8th World-China Pharmaceutical R&D Congress will set sail again, focusing on " Innovative Small Molecular Drugs " with the theme of "Build Innovative Small Molecular Drugs Barriers to Competitiveness, Meet the Challenges of Druggability and NDA", moving from pseudo-innovation to source innovation.
The conference will set up two parallel sub-forums, which will invite 60+leading enterprises, research scholars, regulatory experts and scientists in the field of small molecule innovative drug R&D. PharmaCon involves 2 days of wonderful sharing and discussion centered on class 1 small molecule innovative drugs in tumor and non-tumor fields under new technology platform (PROTAC/ AIDD/CADD/SBDD/FBDD/DEL, etc.) and changes in CMC and NDA application challenges to accelerate differentiated project initiation, drug discovery and CMC NDA process of innovative small-molecule drugs!
★ To catch them all! From the drug discovery to CMC to address the practical challenges of small molecule innovative drug development
★ To track leading practices in the development of innovative small molecule drugs targeting the "undruggable"
★ To analyze of cutting-edge innovation platform technologiesand hot categories: innovative drugs under PROTAC/ molecular glue and more TPD, AIDD/CADD/SBDD/FBDD/DEL and more……
★ To listen to the latest advances in the areas of oncology, IO, and non-tumor (Anti-Infectives, CNS)
★ To learn CMC coping strategies for clinical and post-marketing change and examination
★ To master the notes of NDA application for innovative drugs in the last mile sprint and CMC development strategy that begins with the end in mind